MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Clearmind Medicine (CMND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Clearmind Medicine is the larger company by market cap ($1.3 million vs $982,950), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%CMND-60.15%
+669%+287%-95%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%CMND-60.03%
+681%+293%-95%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus CMND key metrics
MetricBDRXCMND
Share price$1.88$2.63
Market cap$982.95K$1.33M
1-day change-3.85%-17.68%
P/E ratio (TTM)0.00—
EPS (TTM)$509.89$-461.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-3.86M
52-week high$357.60$649.60
52-week low$1.85$2.63
Distance from 52-week high-99.48%-99.60%
Analyst consensusnone—
Avg. price target upside+375.20%—
Average volume618.91K55.57K
Shares outstanding524.24K507.40K
Employees11—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Clearmind Medicine

CMND stock →

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.

Health Care · Biotechnology: Pharmaceutical Preparations

BDRX vs CMND FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Clearmind Medicine?

Clearmind Medicine (CMND) is larger, with a market capitalization of $1.33M compared with $982.95K for Biodexa Pharmaceuticals American Depositary Shs (BDRX).

Are Biodexa Pharmaceuticals American Depositary Shs and Clearmind Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons